267 450

Cited 5 times in

The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(®) study.

Authors
 Y C Hwang  ;  J G Kang  ;  K J Ahn  ;  B S Cha  ;  S H Ihm  ;  S Lee  ;  M Kim  ;  B W Lee 
Citation
 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Vol.68(11) : 1338-1344, 2014 
Journal Title
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
ISSN
 1368-5031 
Issue Date
2014
MeSH
Adult ; Aged ; Diabetes Mellitus, Type 2/drug therapy* ; Female ; Glycated Hemoglobin A/analysis ; Humans ; Hypoglycemic Agents/therapeutic use* ; Insulin/analogs & derivatives* ; Insulin/therapeutic use ; Insulin Aspart/therapeutic use ; Insulin Detemir/therapeutic use ; Insulin Glargine/therapeutic use ; Insulin, Long-Acting/therapeutic use ; Male ; Middle Aged ; Prospective Studies
Abstract
AIMS: In this study, we compared the glucose-lowering effectiveness of insulin analogues and their combination according to baseline glycemic status in patients with type 2 diabetes (T2D) from the A1 chieve(®) study conducted in Korea.
METHODS: This sub-analysis from the A1 chieve(®) study was a 24-week prospective, multicenter, non-interventional, open-labelled study. Of the 4058 patients, 3074 patients who had their HbA1c level measured at baseline were included in this sub-analysis. We classified patients into three groups according to baseline HbA1c levels: group I (HbA1c < 7.5%), group II (7.5% ≤ HbA1c < 9.0%) and group III (HbA1c ≥ 9.0%).
RESULTS: Patients in group I showed no significant HbA1c reduction with any insulin regimens (detemir, aspart, detemir and aspart or biphasic aspart 30 (Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark) after 24 weeks of treatment. In group II, although HbA1c was decreased for all insulin regimens, there was no difference in mean HbA1c reduction among the four insulin regimens. In patients with a high baseline HbA1c level (group III), mean HbA1c reduction was the greatest in patients on a basal-bolus regimen (detemir and aspart, -3.50%) and lowest in patients on a bolus regimen (aspart, -1.81%; p < 0.001).
CONCLUSION: For optimal glycaemic control, a basal-bolus regimen may be adequate for Korean patients with poorly controlled T2D (HbA1c ≥ 9.0%).
Files in This Item:
T201404789.pdf Download
DOI
10.1111/ijcp.12482
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Byung Wan(이병완) ORCID logo https://orcid.org/0000-0002-9899-4992
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138540
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links